Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.
Pixel by LabCorp ℠ Offers Self-Collected Testing Anytime, Anywhere to Empower Healthcare Consumers BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, today ...
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the ...
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on ...
BURLINGTON, N.C.--(BUSINESS WIRE)-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it will mark its 50th ...
Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the ...
“Adding Toxikon underscores our commitment to nonclinical development and advances our capabilities for both drug development and medical device testing,” said Dr. Paul Kirchgraber, CEO of Labcorp ...
Laboratory testing plays a critical role in healthcare, informing nearly 70% of clinical decisions and often serving as the first step in diagnosing and managing patient conditions. Yet research shows ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
GlobalData on MSN
NAMSA acquires Labcorp’s medical device testing assets
NAMSA has acquired select assets of Labcorp’s early development medical device testing business, aligning with .
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback